Getinge’s organic sales growth slowed to 2.1% in the third quarter from 4.6% in the previous quarter. The slowdown was driven by persistent weakness in life science capital goods and lumpy ventilator procurement. Shares increased by 2% at the market open on Oct. 21.
Getinge benefits from stable long-term growth trends such as an aging population and increased healthcare spending, which are generally not affected by macroeconomic circumstances.
Getinge’s China business, which we estimate to be roughly 10% of total sales, is facing a slowdown, similar to that of its life science peers.
|
Metric
|
GETI B
|
MDT
|
SYK
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.34 | 16.44 | 21.33 |
Price/Book Value | 2.21 | 2.37 | 4.76 |
Price/Sales | 2.09 | 3.19 | 4.45 |
Price/Cash Flow | 13.60 | 13.35 | 20.37 |
|
Metric
|
GETI B
|
MDT
|
SYK
|
|---|---|---|---|
Quick Ratio | 0.72 | 1.29 | 1.08 |
Current Ratio | 1.25 | 2.07 | 2.16 |
Interest Coverage | 7.91 | 10.12 | — |
|
Metric
|
GETI B
|
MDT
|
SYK
|
|---|---|---|---|
Return on Assets (Normalized) | 6.11% | 8.31% | 11.44% |
Return on Equity (Normalized) | 11.50% | 15.59% | 23.97% |
Return on Invested Capital (Normalized) | 9.40% | 10.57% | 14.10% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|#r$B&Y | LOCK|K>z# | $174B | |||
| Medtronic PLC
MDT
| LOCK|%p&J%^ | LOCK|x!rsC | $119B | |||
| Stryker Corp
SYK
| LOCK|vw$%!@d> | LOCK|gR% | $114B | |||
| Boston Scientific Corp
BSX
| LOCK|#$#K^H | LOCK|L&%# | $65B | |||
| Edwards Lifesciences Corp
EW
| LOCK|K>>NxcMK | LOCK|Vt#& | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|>B<FH$ | LOCK|fHy | $31B | |||
| DexCom Inc
DXCM
| LOCK|kmx#?T$ | LOCK|<rhH | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|h<k | LOCK|@W@ | $26B | |||
| Steris PLC
STE
| LOCK|c<%#hk? | LOCK|@B#L | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|F!MGyF!# | LOCK|#R | $18B |
United States